Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH

Please Log In/Join Now first, and then use this function!

Not Yet Recruiting

A First-in-Human Study to Assess Single and Multiple Doses of BMS-986209 in Healthy Participants - CV017-003

Updated: 5 November, 2019   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1


  • Gender(s)

  • 18-55

    Age Range

  • 2


  • Not Yet Recruiting

Treatment Options

Study Arms
Active Comparator: Part A: Fasting
Drug: BMS-986209 Drug: Placebo
Active Comparator: Part A: Fed
Drug: BMS-986209 Drug: Placebo
Active Comparator: Part B: Fasting
Drug: Placebo Drug: BMS-986209
Active Comparator: Part B: Fed
Drug: Placebo Drug: BMS-986209

Key Eligibility Criteria

Inclusion Criteria: - Signed informed consent form - Body mass index (BMI) 18.0 to 32.0 kg/m2, inclusive. (BMI = weight (kg)/height[m])2. - Normal renal function at screening. - Female participants not of child-bearing potential. - Males who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception: to use a condom during the intervention period and for at least 92 days after the last dose of study intervention. Azoospermic males are exempt from contraceptive requirements. - Males with a pregnant or breastfeeing partner must agree to remain abstinent from penile vaginal intercourse or use a male condom during each episode of such intercourse, during the intervention period and for at least 92 days after the last dose of study intervention. - Male participants must refrain from donating sperm during the intervention period and for at least 92 days after the last dose of study intervention. Exclusion Criteria: - Women who are of childbearing potential. - Women who are breastfeeding. - Any acute or chronic medical illness. - History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for a 1-week duration in the last month prior to study treatment administration). - History of heart disease or conduction disorders. - Head injury in the last 2 years, intracranial tumor, or aneurysm. - Current or history of rectal bleeding, hematemesis, or hematuria. - Known abdominal aneurysm. - History of gastroesophageal reflux disease, inflammatory bowel disease or any gastrointestinal disease that could impact the absorption of study treatment. - History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding, such as epistaxis. - Personal or family history of hemophilia, Rosenthal syndrome, FXIa deficiency, or other coagulopathies. - History of systemic lupus erythematosus or any other autoimmune diseases. - Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study. - Donation of blood to a blood bank or in a clinical study (except a screening visit or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only). - Current or any history of blood transfusion. - Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study treatment administration). - Current or history of drug or alcohol abuse. Other protocol-defined inclusion/exclusion criteria may apply.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us